Condition (MeSH)
Nijmegen Breakage Syndrome
ClinicalTrials.gov lists 3 trials for Nijmegen Breakage Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
3 sections measured, none recorded · 1 not measured yet · 1 not computed
3 of the 3 trials are tagged with Nijmegen Breakage Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Nijmegen Breakage Syndrome trials start? (3)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 1 |
| 2020 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Nijmegen Breakage Syndrome trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Phase 2 | 3 |
How many Nijmegen Breakage Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Nijmegen Breakage Syndrome? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders. | The Lancet. Neurology | 2022 | Yes |
| Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease. | Alimentary pharmacology & therapeutics | 2022 | Yes |
| Maternal Predictors of Breast Milk Plasmalogens and Associations with Infant Body Composition and Neurodevelopment. | Clinical therapeutics | 2022 | Yes |
| Fertility defects revealing germline biallelic nonsense NBN mutations. | Human mutation | 2009 | No |
Prevalence (24)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Nijmegen breakage syndrome | Point prevalence | 1-9 / 1 000 000 | Poland | Not stated | Exact |
| Nijmegen breakage syndrome | Point prevalence | 1-9 / 1 000 000 | Slovakia | Not stated | Exact |
| Nijmegen breakage syndrome | Point prevalence | 1-9 / 1 000 000 | Belarus | Not stated | Unspecified |
| Nijmegen breakage syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Nijmegen breakage syndrome | Point prevalence | 1-9 / 1 000 000 | Slovakia | Not stated | Unspecified |
Showing 5 of 24 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Nijmegen breakage syndrome | 647 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Nijmegen breakage syndrome | 647 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.